- Home
- INAB vs SNES Comparison
INAB vs SNES Comparison
Compare INAB & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INAB | SNES |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 12.1M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | INAB | SNES |
|---|---|---|
| Price | $1.51 | $1.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 58.0K | 19.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.99 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $600,000.00 |
| Revenue This Year | N/A | $29.00 |
| Revenue Next Year | N/A | $95.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.56 |
| 52 Week Low | $0.12 | $1.41 |
| 52 Week High | $4.20 | $5.99 |
Technical Indicators
Market Signals| Indicator | INAB | SNES |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 47.01 |
| Support Level | $1.35 | N/A |
| Resistance Level | $2.11 | $1.75 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 65.17 | 60.71 |
Price Performance
Historical ComparisonAbout INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.